Remove tag car-t
article thumbnail

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

FDA 95
article thumbnail

PharmaShots Weekly Snapshots (April 10 - 14, 2023)

PharmaShots

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

Australian biotechnology company Cartherics has granted licence for CTH-004 , its autologous CAR-T cell product, to Chinese company Shunxi. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP. In animal models of ovarian cancer, it demonstrated promising results.

52
article thumbnail

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

PharmaShots

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA 40
article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. CellCentric, a U.K-based

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

More than a decade after the first patient was treated with a CAR-T therapy, six therapies relying on the same principles have been approved by the US Food and Drug Administration (FDA) and marketed to thousands of patients. Bruce Levine [BL]: We now have six approved CAR-T therapies.

FDA 59
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

The most widely utilised IO class is immune checkpoint inhibitors (ICIs), which work by blocking the inhibitory interactions between tumour cells and T-cells, facilitating an anti-tumour immune response. There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications.